Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudia Cardone

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Medical Oncology (Northwood, London, England)|February 11, 2021
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotypeDavide Ciardiello, Bernadette Blauensteiner, Nunzia Matrone, et al.
JAMA Oncology|May 18, 2023
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical TrialStefania Napolitano, Vincenzo De Falco, Giulia Martini, et al.
Cancers|October 11, 2019
Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution ExperiencePietro Paolo Vitiello, Vincenzo De Falco, Emilio Francesco Giunta, et al.
Molecular Cancer Therapeutics|March 3, 2019
EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal CancerGiulia Martini, Claudia Cardone, Pietro Paolo Vitiello, et al.
JAMA Oncology|August 12, 2021
Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE TrialErika Martinelli, Giulia Martini, Vincenzo Famiglietti, et al.
European Journal of Cancer (Oxford, England : 1990)|August 21, 2020
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancerClaudia Cardone, Bernadette Blauensteiner, Veronica Moreno-Viedma, et al.
Journal of Translational Medicine|October 22, 2020
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trialFrancesco Perrone, Maria Carmela Piccirillo, Paolo Antonio Ascierto, et al.
ESMO Open|March 4, 2017
Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO)Gilberto Morgan, Matteo Lambertini, Hampig Raphael Kourie, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Medical Oncology (Northwood, London, England)|February 11, 2021
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotypeDavide Ciardiello, Bernadette Blauensteiner, Nunzia Matrone, et al.
JAMA Oncology|May 18, 2023
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical TrialStefania Napolitano, Vincenzo De Falco, Giulia Martini, et al.
Cancers|October 11, 2019
Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution ExperiencePietro Paolo Vitiello, Vincenzo De Falco, Emilio Francesco Giunta, et al.
Molecular Cancer Therapeutics|March 3, 2019
EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal CancerGiulia Martini, Claudia Cardone, Pietro Paolo Vitiello, et al.
JAMA Oncology|August 12, 2021
Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE TrialErika Martinelli, Giulia Martini, Vincenzo Famiglietti, et al.
European Journal of Cancer (Oxford, England : 1990)|August 21, 2020
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancerClaudia Cardone, Bernadette Blauensteiner, Veronica Moreno-Viedma, et al.
Journal of Translational Medicine|October 22, 2020
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trialFrancesco Perrone, Maria Carmela Piccirillo, Paolo Antonio Ascierto, et al.
ESMO Open|March 4, 2017
Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO)Gilberto Morgan, Matteo Lambertini, Hampig Raphael Kourie, et al.
Pageof 4